Gastrointestinal bleeding secondary to the new anticoagulants

Neena S. Abraham, Jennifer L. Horsley-Silva

Research output: Contribution to journalReview articlepeer-review

10 Scopus citations


Purpose of review To quantify direct oral anticoagulants (DOACs) related gastrointestinal bleeding (GIB), characterize patients at greatest risk and provide a pragmatic approach for the management of these drugs. This review will also summarize risk-management strategies and highlight evolving areas of clinical knowledge. Recent findings DOACs permit anticoagulation with predictable dosing without the need for routine serum monitoring. Since their availability on the market, they have quickly emerged as a popular alternative for patients requiring short-term and lifelong anticoagulation. However, they are associated with an increased risk of GIB when compared with warfarin; thus, gastroenterologists must be prepared to manage DOACrelated GIB and prevent drug-related complications. This review will focus on acute and elective periendoscopic DOAC management, high-risk clinical groups for DOAC-related GIB, quantification of DOAC levels, use of reversal agents and minimization of thromboembolic risk associated with temporary interruption. Summary This review will highlight pragmatic strategies for the treatment of DOAC-related bleeding and the prevention of postendoscopic DOAC bleeding. It will address new and evolving areas of periendoscopic management and identify knowledge gaps requiring further research to inform clinical practice.

Original languageEnglish (US)
Pages (from-to)474-480
Number of pages7
JournalCurrent Opinion in Gastroenterology
Issue number6
StatePublished - Oct 23 2016


  • Apixaban
  • Dabigatran
  • Edoxaban
  • Endoscopy
  • Rivaroxaban
  • Temporary interruption

ASJC Scopus subject areas

  • Gastroenterology


Dive into the research topics of 'Gastrointestinal bleeding secondary to the new anticoagulants'. Together they form a unique fingerprint.

Cite this